FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | Sample | Privacy
Related Topics >> India | Generic Drugs | Counterfeit Drugs

India cites deliberate "generic" vs. "counterfeit" confusion

Free Newsletter

FiercePharma Manufacturing provides must-know news and insight on the hardware and software tools used to automate pharmaceutical manufacturing. Sign up today to receive your FREE "insiders only" weekly pharma manufacturing industry briefing.



Tools

The persistent seizure of Indian generics at European ports may be a terminology issue. A representative from India, speaking at a World Health Organization meeting, suggests that port authorities may be confusing the terms "counterfeit" and "generic."

India says the EU has provided information on 26 drug-shipment seizures in 17 European countries relating to intellectual-property violations. But Indian officials are still waiting to hear if European authorities found any substandard medicines, Intellectual Property Watch reports.

European officials say that such mistaken seizure of legitimate generic drugs ended in 2008.

"We have concerns regarding the use of the term 'counterfeit,'" India says in a statement to the meeting. The term "counterfeit" is more closely aligned with trademark issues rather than the quality, safety and efficacy issues that should drive health officials' judgments concerning drug shipments, say representatives from India, Brazil and other countries. The intellectual-property perspective introduces a "deliberate confusion" of the issue by those who want to increase IP enforcement.

- read the article

Related Articles:
UK groups take on anti-counterfeiting projects
Americans distrust drugs from China, India


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Manufacturing Email Newsletter:

More stories about India   Generic Drugs   Counterfeit Drugs